This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes — C26 (Malignant neoplasm of other and ill-defined digestive organs) |
| B. | Synonyms — Malignant tumor of unspecified digestive tract site, unspecified cancer of the digestive system, digestive cancer NOS |
| C. | Adult onset — Very high (varies by type of tumor included; mostly from middle age onward) |
| 1. | History — Background of the C26 code; history of the clinical and pathologic classification of digestive tract cancer NOS; CUP epidemiology |
| 2. | Causes — Risk factors for gastrointestinal cancer NOS: smoking, alcohol, chronic inflammation, diet, obesity, genetic predisposition |
| 3. | Genetics — Common molecular pathways of digestive cancer NOS; molecular features related to KRAS, TP53, APC, and MLH1 MSI |
| 4. | Epidemiology — Statistical significance of the C26 code; overall burden of digestive malignancies; registration patterns of cancer NOS |
| 5. | Pathophysiology — Digestive mucosal injury, inflammation, dysplasia, invasion; special mechanisms of digestive GIST and NET |
| 6. | Symptoms — Abdominal pain, indigestion, bleeding, weight loss, jaundice (with biliary involvement), bowel obstruction, ascites |
| 7. | Signs — Abdominal mass, hepatomegaly, jaundice, ascites, cachexia, elevated CA19-9, CEA, and AFP |
| 8. | Screening — Site-specific cancer screening (colonoscopy, gastroscopy, abdominal ultrasound); no specific screening for digestive system NOS |
| 9. | Diagnosis — Abdominal CT/MRI, PET-CT, endoscopy, biopsy, immunohistochemistry, molecular profiling, CUP diagnostic algorithm |
| 10. | Treatment — Tailored treatment by histologic type and site; empirical chemotherapy for cancer of unknown primary (CUP); supportive care |
| 11. | Prognosis — Poor prognosis for cancer of unknown primary (median OS 3–12 months); varies greatly with histologic type and molecular features |
| 12. | Prevention — Smoking cessation, moderation of alcohol intake, obesity management, prevention and treatment of digestive infections (H. pylori), regular health checkups |
| 13. | References — WHO classification of digestive system tumours, NCCN CUP guidelines, Korean cancer statistics, and molecular carcinogenesis references (10 in total) |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C26 — Malignant neoplasm of other and ill-defined digestive organs |
| Subcodes | C26.0 intestinal tract (part unspecified), C26.1 spleen, C26.9 ill-defined sites within the digestive system |
| Scope | Digestive malignancies not included in C15–C25; overlapping lesions; cancer of unknown primary site in the digestive tract; digestive cancer of unknown primary that is not a secondary lesion of the peritoneum or omentum |
| Special Copayment Reduction code | V193 |
| Note | Assigned to malignancies of the alimentary tract/canal when the location cannot be specified; digestive GIST and neuroendocrine tumors (NET) may also be included depending on histologic type |
Digestive malignancy NOS (not otherwise specified), malignant neoplasm of the digestive tract, unspecified, gastrointestinal malignancy NOS, digestive system cancer of unknown primary, malignant neoplasm of digestive tract NOS, malignant neoplasm of gastrointestinal tract NOS. In clinical and pathologic coding, it applies when the primary site has not been clearly identified or to overlapping lesions spanning two or more digestive organs. Primary malignant tumors of the spleen (C26.1) are also included in this category.
Digestive malignancies classified under code C26 tend to show a very high frequency of adult onset. The age of onset varies with the type of tumor included, but most are diagnosed from middle age (50s–70s) onward. With hereditary predisposition (Lynch syndrome, FAP, etc.), they can occur at younger ages. They are extremely rare in children.
In the ICD classification system, 'other and ill-defined sites (C26)' of digestive malignancies is a residual category covering malignancies whose primary site cannot be precisely specified or that are overlapping lesions spanning several digestive organs. The history of this code has evolved along with the ICD classification system. After Virchow established cellular pathology in the late 19th century, the anatomic classification of digestive cancers began to be systematized, and digestive malignancies have been classified independently since ICD-6 (1948).
Clinically, carcinoma of unknown primary (CUP) accounts for about 3–5% of all cancers, and CUP presumed to be of digestive origin accounts for a considerable portion of these. The history of CUP became systematized as attempts to trace back the primary site increased with advances in immunohistochemistry (IHC) techniques. From the 1990s, estimation of the primary site using immunomarkers such as cytokeratin subtypes (CK7, CK20), CDX2, and TTF-1 became possible, and since the 2000s, with the introduction of gene expression profiling and next-generation sequencing (NGS), the accuracy of identifying the primary site of CUP has greatly improved.
Primary malignant tumors of the spleen (C26.1) are very rare, mostly lymphomas or angiosarcomas, and primary splenic carcinoma is extremely rare. Digestive neuroendocrine tumors (GEP-NET), formerly called 'carcinoids,' were redefined in the WHO 2019 classification, and NETs of digestive organ origin may in part be included in the C26 category. Gastrointestinal stromal tumors (GIST), owing to their distinctive molecular features caused by KIT/PDGFRα variants, became a representative success story of imatinib targeted therapy.
Risk factors common across digestive malignancies include smoking (increased risk of esophageal, gastric, pancreatic, and colorectal cancer), excessive alcohol intake (increased risk of esophageal, oral, liver, and colon cancer), obesity (increased risk of esophageal adenocarcinoma and colon, liver, gallbladder, and pancreatic cancer), chronic inflammation (H. pylori infection → gastric cancer, inflammatory bowel disease → colorectal cancer), and dietary imbalance (excess red and processed meat, lack of vegetables and fruits).
Site-specific risk factors include H. pylori infection (gastric cancer), GERD and Barrett esophagus (esophageal adenocarcinoma), smoking, alcohol, and vitamin deficiency (esophageal squamous cell carcinoma), HBV/HCV, alcohol, and aflatoxin (liver cancer), gallstones and chronic cholecystitis (gallbladder cancer), PSC and choledochal cysts (cholangiocarcinoma), smoking, diabetes, and chronic pancreatitis (pancreatic cancer), and inflammatory bowel disease (colorectal cancer). In cancers of unknown primary classified under digestive code C26, the risk factors are often combined or unclear.
Lynch syndrome (MMR gene variants), familial adenomatous polyposis (APC variants), Peutz-Jeghers syndrome (STK11 variants), hereditary diffuse gastric cancer (CDH1 variants), and BRCA1/2 variants are known hereditary predispositions to digestive malignancies.
The molecular genetics of digestive malignancies differ by primary site and histologic type, but there are important common driver genes. KRAS variants are key oncogenic mutations commonly observed in pancreatic cancer (~90%), colorectal cancer (~40%), cholangiocarcinoma (~20%), lung adenocarcinoma, and others. TP53 variants accumulate at late stages of carcinogenesis in most digestive cancers. APC variants (the earliest event in colorectal cancer, activating the Wnt/β-catenin pathway) act as the 'gatekeeper' of colorectal carcinogenesis.
In molecular characterization of cancer of unknown primary (CUP), the primary site is traced back through gene expression profiling and NGS. CDX2 (suggesting gastrointestinal origin), CK20 (suggesting colon/gallbladder), CK7 (suggesting stomach/pancreas/bile duct), CK19 (suggesting bile duct/pancreas), and AFP (suggesting liver/germ cell) are used as immunohistochemical markers. MSI-H (microsatellite instability-high) and TMB-H are biomarkers predicting response to immunotherapy and are important in treatment decisions regardless of primary site. NTRK fusions, RET fusions, and MET amplification are also rare but clinically meaningful targets in digestive malignancies.
In cancer registry statistics, the C26 code itself is a 'residual' category, and its share of all digestive malignancies varies with national coding practices, diagnostic precision, and frequency of autopsy. In developed countries, as high-resolution imaging and endoscopic techniques advance, the number of cases classified as C26 is decreasing. In Korea, digestive malignancies as a whole (C15–C26) are estimated at about 60,000–70,000 cases per year, of which C26 accounts for a small minority.
Looking at digestive malignancies as a whole, colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, esophageal cancer, and gallbladder/bile duct cancer account for most digestive cancer deaths. Digestive cancers are a major cancer group, accounting for about 35–40% of cancer incidence worldwide. Cancer of unknown primary (CUP) accounts for about 3–5% of all cancers and has a poor prognosis because it is already metastatic at diagnosis. Primary malignant tumors of the spleen are extremely rare, accounting for less than 0.1% of all cancers.
Malignancies under code C26 include a clinically heterogeneous group of tumors but share common digestive carcinogenic mechanisms. Digestive epithelial cells normally show rapid cell turnover, providing many opportunities for genetic alterations to accumulate. Chronic inflammation (H. pylori, inflammatory bowel disease, bile reflux), oxidative stress, and DNA damage and repair defects are the key mechanisms of carcinogenesis.
Gastrointestinal stromal tumors (GIST) arise from interstitial cells (cells of Cajal) in the wall of the digestive tract, and KIT (80%) or PDGFRα (5–10%) activating variants cause constitutive tyrosine kinase signaling that drives cell proliferation. Digestive neuroendocrine tumors (NET) arise from neuroendocrine cells, and MEN1 variants, DAXX/ATRX variants, and TSC1/2 variants are characteristic of pancreatic NET. Primary peritoneal malignancies (peritoneal mesothelioma, etc.) arise through a separate mechanism associated with asbestos exposure.
Because C26 malignancies vary in location and histologic type, their symptoms are often nonspecific. Abdominal pain is the most common symptom, with location and character differing by primary site. Indigestion, nausea, vomiting, loss of appetite, and weight loss (cachexia) commonly accompany. Gastrointestinal bleeding (hematemesis, hematochezia, melena) and anemia may occur, and it is sometimes detected as occult blood.
When the tumor invades the biliary system, jaundice, pruritus, and dark urine appear. Symptoms of bowel obstruction (abdominal distension, vomiting, cessation of bowel movements), ascites due to peritoneal metastasis, and hepatomegaly and jaundice due to liver metastasis are also observed. NETs are characterized by symptoms due to hormone secretion (carcinoid syndrome such as flushing, diarrhea, and hypoglycemia).
On physical examination, an abdominal mass, hepatomegaly (metastatic or primary), jaundice (bile duct invasion or liver metastasis), ascites (peritoneal dissemination), cachexia (weight loss, muscle wasting), skin jaundice, and lymphadenopathy may be observed. Serum tumor markers used include CA19-9 (suggesting biliary/pancreatic origin), CEA (suggesting colorectal origin), AFP (suggesting liver origin or germ cell tumor), and CA125 (suggesting peritoneal/ovarian origin). Abnormalities in liver function tests, bilirubin, complete blood count, serum electrolytes, and nutritional indicators (albumin, prealbumin) accompany.
There is no specific screening program for C26 (malignancy of ill-defined digestive sites) itself. Instead, site-specific national cancer screening for digestive malignancies is useful. The Korean National Cancer Screening Program provides screening for gastric cancer (age 40 or older, gastroscopy or upper GI series every 2 years) and colorectal cancer (age 50 or older, fecal occult blood test every year, with colonoscopy if abnormal). Liver cancer (high-risk groups, abdominal ultrasound + AFP every 6 months) is also included. Prevention of gastric cancer through H. pylori testing and treatment and prevention of colorectal cancer through detection and removal of colorectal polyps are important. Early and intensive surveillance is needed in hereditary high-risk groups such as Lynch syndrome.
Abdominal and pelvic CT (dynamic contrast-enhanced) is essential for evaluating intra-abdominal masses, estimating the primary site, and assessing metastasis. Abdominal MRI is used complementarily to characterize liver lesions and evaluate peritoneal metastasis. PET-CT is used to evaluate systemic metastasis. Upper and lower GI endoscopy (gastroscopy, colonoscopy) is used to directly observe and biopsy mucosal lesions. Small bowel endoscopy (capsule endoscopy, double-balloon endoscopy) is used to evaluate primary small bowel tumors.
Immunohistochemistry (IHC): the primary site is traced back using the CK7/CK20 pattern, CDX2, TTF-1, CDX2, SATB2, AFP, synaptophysin/chromogranin (NET), and so on. Next-generation sequencing (NGS) panels analyze KRAS, TP53, APC, BRAF, HER2, MSI status, TMB, NTRK fusions, RET, and more. In cancer of unknown primary, estimation of the primary site is attempted by gene expression profiling (Pathwork Tissue of Origin, etc.).
When the primary site has been identified by imaging or pathology, the standard treatment guidelines for that cancer are followed (see each condition under C15–C25). In digestive GIST, imatinib (KIT/PDGFRα inhibitor) is the standard systemic therapy. In digestive NET (low-grade), everolimus (mTOR inhibitor), sunitinib (TKI), and somatostatin analogs (octreotide, lanreotide) are used.
In CUP presumed to be of digestive origin, empirical chemotherapy such as paclitaxel + carboplatin or gemcitabine + cisplatin is used. In MSI-H/TMB-H CUP, immune checkpoint inhibitors such as pembrolizumab and nivolumab are effective. For NTRK fusion-positive cancers, larotrectinib and entrectinib have been approved as tissue-agnostic therapy. Supportive care for symptom relief and improved quality of life (pain management, nutritional support, biliary drainage, feeding tube placement, etc.) is provided concurrently.
The prognosis of digestive malignancies classified under code C26 differs greatly by primary site, histologic type, and stage. In general, cancer of unknown primary (CUP) has a poor prognosis with a median OS of about 3–12 months, but the prognosis may improve when the primary site can be estimated and the tumor responds to targeted therapy or immunotherapy. For digestive GIST, 5-year survival has improved greatly since the introduction of imatinib (5-year survival of resectable GIST about 60–70%). The prognosis of digestive NET differs greatly by grade: low-grade NETs have 5-year survival of 60–90%, whereas high-grade neuroendocrine carcinoma (NEC) is very poor. Digestive malignancies with peritoneal metastasis generally have a poor prognosis.
Smoking cessation: effective in preventing many digestive cancers. Moderation of or abstinence from alcohol: reduces the risk of alcohol-related liver, esophageal, and colorectal cancer. Obesity management: maintain weight through regular exercise and a balanced diet. Prevention and treatment of infections: H. pylori testing and eradication (gastric cancer prevention), HBV vaccination and antiviral treatment (liver cancer prevention), deworming for liver flukes (cholangiocarcinoma prevention). Regular health checkups: early detection through the Korean National Cancer Screening Program (gastric, colorectal, and liver cancer). Dietary control: limit red and processed meat, increase intake of vegetables, fruits, and dietary fiber, reduce salt intake. Management of hereditary high-risk groups: in identified high-risk groups such as Lynch syndrome and FAP, early-starting regular endoscopic surveillance and consideration of prophylactic surgery.